- Home
- ZUMZ vs LYEL Comparison
ZUMZ vs LYEL Comparison
Compare ZUMZ & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZUMZ | LYEL |
|---|---|---|
| Founded | 1978 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 363.1M | 369.4M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZUMZ | LYEL |
|---|---|---|
| Price | $29.42 | $34.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $18.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 302.8K | 57.7K |
| Earning Date | 12-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $916,909,000.00 | $41,000.00 |
| Revenue This Year | $5.50 | N/A |
| Revenue Next Year | $1.36 | N/A |
| P/E Ratio | $58.96 | ★ N/A |
| Revenue Growth | ★ 2.81 | N/A |
| 52 Week Low | $11.31 | $7.65 |
| 52 Week High | $31.70 | $35.16 |
Technical Indicators
Market Signals| Indicator | ZUMZ | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 70.19 | 80.73 |
| Support Level | $28.55 | $20.59 |
| Resistance Level | $31.70 | $35.16 |
| Average True Range (ATR) | 1.24 | 2.50 |
| MACD | 0.17 | 1.12 |
| Stochastic Oscillator | 71.51 | 92.69 |
Price Performance
Historical ComparisonAbout ZUMZ Zumiez Inc.
Zumiez Inc is a United-States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art from action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.